Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NeOnc (NASDAQ: NTHI) is entering one of the most significant periods after securing its second IND from the UAE
-
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
-
NeOnc’s (NASDAQ: NTHI) recent Abu Dhabi IND authorization for NEO212 highlights an increasingly attractive pharmaceutical industry development strategy
-
NeOnc(NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator
-
our names that have emerged as closely watched stories spanning biotechnology, AI, aerospace, communications, and digital infrastructure
-
NeOnc Technologies Holdings (NASDAQ: NTHI) continues to build momentum as a neuro-oncology sector trailblazer
-
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
-
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026The Phase 1 monotherapy...
-
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026The Phase 1 monotherapy...
-
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) --...